TY - JOUR A1 - Yildirim-Semerci, Cigdem A1 - Benayahu, Dafna A1 - Adamovski, Miriam A1 - Wollenberger, Ursula T1 - An Electrochemical Assay for Monitoring Differentiation of the Osteoblastic Cell Line (MBA-15) on the Sensor Chip JF - Electroanalysis : an international journal devoted to fundamental and practical aspects of electroanalysis N2 - An electrochemical assay for the indication of the activity of the cell bound differentiation marker alkaline phosphatase (ALP) is proposed using voltammetry on an in-vitro cell culture. The basis of the assay is cultivation of cells on gold microelectrodes in wells of a microplate, catalytic hydrolysis of p-aminophenyl phosphate by ALP and indication of p-aminophenol oxidation by square wave voltammetry (SWV) with the sensors onto which the cells attached. The morphology of the bone marrow stromal cell line (MBA-15) on the electrode surface was investigated and it exhibited in vitro osteogenic characteristics. Since ALP is expressed on the cell surface in early differentiation stage of osteoblastic cells, its activity was followed after different culture times over a period of 144 h by recording repetitive voltammograms at different time points upon addition of the substrate p-aminophenyl phosphate. The ALP activity was estimated from the signal increase related to formation rate of p-aminophenol and the number of cells. The highest value was measured at 120 h, when the cells reached confluence. The results of the electrochemical activity assay are consistent with the colorimetric acquired value from p-nitrophenol formation rate. KW - Alkaline phosphatase KW - Osteoblast KW - Voltammetry KW - Biomarker KW - p-Aminophenol Y1 - 2015 U6 - https://doi.org/10.1002/elan.201400684 SN - 1040-0397 SN - 1521-4109 VL - 27 IS - 6 SP - 1350 EP - 1358 PB - Wiley-VCH CY - Weinheim ER - TY - THES A1 - Stößel, Daniel T1 - Biomarker Discovery in Multiple Sclerosis and Parkinson’s disease T1 - Biomarkerentwicklung in Multiple Sklerose und der Parkinson-Krankheit BT - novel insights into metabolic disease mechanisms N2 - Neuroinflammatory and neurodegenerative diseases such as Parkinson's (PD) and multiple sclerosis (MS) often result in a severe impairment of the patient´s quality of life. Effective therapies for the treatment are currently not available, which results in a high socio-economic burden. Due to the heterogeneity of the disease subtypes, stratification is particularly difficult in the early phase of the disease and is mainly based on clinical parameters such as neurophysiological tests and central nervous imaging. Due to good accessibility and stability, blood and cerebrospinal fluid metabolite markers could serve as surrogates for neurodegenerative processes. This can lead to an improved mechanistic understanding of these diseases and further be used as "treatment response" biomarkers in preclinical and clinical development programs. Therefore, plasma and CSF metabolite profiles will be identified that allow differentiation of PD from healthy controls, association of PD with dementia (PDD) and differentiation of PD subtypes such as akinetic rigid and tremor dominant PD patients. In addition, plasma metabolites for the diagnosis of primary progressive MS (PPMS) should be investigated and tested for their specificity to relapsing-remitting MS (RRMS) and their development during PPMS progression. By applying untargeted high-resolution metabolomics of PD patient samples and in using random forest and partial least square machine learning algorithms, this study identified 20 plasma metabolites and 14 CSF metabolite biomarkers. These differentiate against healthy individuals with an AUC of 0.8 and 0.9 in PD, respectively. We also identify ten PDD specific serum metabolites, which differentiate against healthy individuals and PD patients without dementia with an AUC of 1.0, respectively. Furthermore, 23 akinetic-rigid specific plasma markers were identified, which differentiate against tremor-dominant PD patients with an AUC of 0.94 and against healthy individuals with an AUC of 0.98. These findings also suggest more severe disease pathology in the akinetic-rigid PD than in tremor dominant PD. In the analysis of MS patient samples a partial least square analysis yielded predictive models for the classification of PPMS and resulted in 20 PPMS specific metabolites. In another MS study unknown changes in human metabolism were identified after administration of the multiple sclerosis drug dimethylfumarate, which is used for the treatment of RRMS. These results allow to describe and understand the hitherto completely unknown mechanism of action of this new drug and to use these findings for the further development of new drugs and targets against RRMS. In conclusion, these results have the potential for improved diagnosis of these diseases and improvement of mechanistic understandings, as multiple deregulated pathways were identified. Moreover, novel Dimethylfumarate targets can be used to aid drug development and treatment efficiency. Overall, metabolite profiling in combination with machine learning identified as a promising approach for biomarker discovery and mode of action elucidation. N2 - Neuroinflammatorische and neurodegenerative Erkrankungen wie Parkinson (PD) und Multiple Sklerose (MS) gehen oft mit einer starken Beeinträchtigung der Lebensqualität einher. Effektive Therapien für die Behandlung sind derzeit nicht verfügbar, was nicht zuletzt eine hohe sozioökonomische Last zur Folge hat. Aufgrund der Heterogenität der Krankheitsbilder ist eine Stratifizierung gerade in der Frühphase der Erkrankung schwierig und basiert hauptsächlich auf klinischen Parametern wie bspw. neurophysiologischen Tests und bildgebenden Verfahren. Aufgrund ihrer guten Zugänglichkeit und Stabilität könnten bestimmte Blut- und Liquor-Metabolitenmarker als Surrogat für neurodegenerative Prozesse dienen, zu einem verbesserten mechanistischen Verständnis dieser Krankheiten führen und nicht zuletzt als “treatment response“ Biomarker in präklinischen und klinischen Entwicklungsprogrammen herangezogen werden. In dieser Arbeit sollten deshalb Plasma- und CSF-Metabolitprofile identifiziert werden, die eine Differenzierung von PD zu gesunden Kontrollen, Assoziierung zu PD mit Demenz (PDD) sowie eine Abgrenzung zu unterschiedlichen PD-Subtypen wie akinetisch-rigiden sowie tremor-dominanten PD-Patienten ermöglichen. Weiterhin wurden in dieser Arbeit Plasmametabolite zur Diagnose von primär-progressiver MS (PPMS) erforscht und auf ihre Spezifität gegenüber schubförmig remittierender MS (RRMS) und PD geprüft sowie deren Verlauf während der PPMS Progression getestet. Hierbei konnten durch “untargeted Metabolomics“ in Kombination mit statistischen Modellen mehrere Plasma- und CSF-Metabolite in PD-Patienten/Erkrankten ermittelt werden, die mit Hilfe von statistischen Diagnosemodellen eine Differenzierung zu gesunden Personen ermöglichen. Darüber hinaus wurden in dieser Arbeit PDD-spezifische Serummetabolite identifiziert, die wiederum genutzt werden können, um diesen PD-Typen von gesunden Individuen und PD-Patienten ohne Demenz abzugrenzen. Des Weiteren konnten bei akinetisch-rigiden PD-Patienten spezifische Metabolite entdeckt werden, die im Vergleich zu tremor-dominanten PD-Patienten eine stärkere metabolische Krankheitssymptomatik suggerieren. Im Zusammenhang mit PPMS wurden in dieser Arbeit spezifische Plasma-Metabolite entdeckt, die zur Diagnose gegen RRMS, PD und gesunden Kontrollen genutzt werden können. Interessanterweise zeigte dabei ein spezifisches Lipid geringere Werte im PPMS Krankheitsverlauf, wodurch sich dieses als möglicher Marker zur Progressionsdiagnostik dieser Krankheit qualifiziert. Abschließend konnten in dieser Arbeit im humanen Stoffwechsel bisher unbekannte Angriffspunkte des Medikaments Dimethylfumarat, das zur Behandlung von RRMS verwendet wird, ermittelt werden. Durch diese Ergebnisse kann der bis jetzt gänzlich unbekannte Wirkungsmechanismus dieses neuen Medikaments besser beschrieben und verstanden, sowie zur Weiterentwicklung neuer Medikamente gegen RRMS genutzt werden. KW - metabolomics KW - biomarker KW - multiple sclerosis KW - Parkinson's disease KW - neurodegeneration KW - neuroinflammation KW - machine-learning KW - Parkinson-Krankheit KW - Biomarker KW - Maschinelles-Lernen KW - Metabolomics KW - Multiple-Sklerose Y1 - 2018 ER - TY - JOUR A1 - Scheller, Frieder W. A1 - Zhang, Xiaorong A1 - Yarman, Aysu A1 - Wollenberger, Ulla A1 - Gyurcsányi, Róbert E. T1 - Molecularly imprinted polymer-based electrochemical sensors for biopolymers JF - Current opinion in electrochemistry N2 - Electrochemical synthesis and signal generation dominate among the almost 1200 articles published annually on protein-imprinted polymers. Such polymers can be easily prepared directly on the electrode surface, and the polymer thickness can be precisely adjusted to the size of the target to enable its free exchange. In this architecture, the molecularly imprinted polymer (MIP) layer represents only one ‘separation plate’; thus, the selectivity does not reach the values of ‘bulk’ measurements. The binding of target proteins can be detected straightforwardly by their modulating effect on the diffusional permeability of a redox marker through the thin MIP films. However, this generates an ‘overall apparent’ signal, which may include nonspecific interactions in the polymer layer and at the electrode surface. Certain targets, such as enzymes or redox active proteins, enables a more specific direct quantification of their binding to MIPs by in situ determination of the enzyme activity or direct electron transfer, respectively. KW - Electropolymerization KW - Direct electron transfer KW - Redox marker KW - Epitope imprinting KW - Biomarker Y1 - 2018 U6 - https://doi.org/10.1016/j.coelec.2018.12.005 SN - 2451-9103 VL - 14 SP - 53 EP - 59 PB - Elsevier CY - Amsterdam ER -